Alnylam Pharmaceuticals, Inc. (ALNY) Price to Earnings Ratio

Corporate emblem and logo of Alnylam Pharmaceuticals, Inc. (ALNY)

The defensive status of Alnylam Pharmaceuticals (ALNY) ensures an absence of seasonality and cyclical downturns. The company's P/E ratio demonstrates price stability, while the value of 7.80 shows the most recent multiple. Financial reserves are bolstered by the implementation of sustainable ESG standards in production and immense pricing power within the unique RNA therapy segment, which allows for high treatment costs for rare pathologies.

Alnylam Corp (ALNY) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Alnylam (ALNY)

General company analysis:Alnylam Pharmaceuticals, Inc. - ALNY
Original product of alnylam.com

Alnylam Pharmaceuticals (ALNY) dominates the RNA interference segment, possessing exceptional pricing power within the orphan disease niche. By analyzing the company's forward P/E, an investor assesses the market value of one dollar of net income. This ratio mathematically strips market noise from quotes, revealing the business's real value relative to its earnings. Its monopoly status and the inelastic demand for therapy make such multiples the foundation for determining the asset's fair value.